Document is current

Article History

Received: 16 April 2023

Accepted: 25 April 2023

First Online: 10 May 2023

Declarations

:

: MJGTV received research Grants from 3M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical, as well as speaker fees or consulting fees from Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-Mérieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH, Tillots Pharma GmbH. CFM has given talks at Ferring-sponsored symposia. AS has been lecturing for AbbVie, Bristol Myers Squibb, Celltrion, CLS Behring, De Prom, Falk Foundation, Ferring, Janssen, Kompetenznetz Darmerkrankungen, MedUpdate, MSD, Recordati-Pharma, sobi rare strength, Takeda and consulting activities for AbbVie, Amgen, Bristol Myers Squibb, Consal, Galapagos, Gilead, Janssen, Lilly, MSD, Repha GmbH, Roche, Pfizer, Pharmacosmos GmbH, Takeda, Tillots Pharma GmbH. SS has received personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius Kabi, IMAB, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda and Theravance. HJE received speaker fees or consulting fees from Astellas Pharma, Falk Foundation, Ferring Arzneimittel, MSD, Tillots Pharma, viiv Health care. JO and LvM stated no conflicts of interest.

: The risks for the participants were considered minimal, so no requirement of ethical approval was deemed necessary. This study was conducted in accordance with the principles of the Declaration of Helsinki.

: Not applicable.

: Not applicable.